Boshengji Pharmaceutical's CD7-targeted CAR-T cell injection obtained the U.S. FDA orphan drug designation

Recently, Boshengji Pharmaceutical Technology (Suzhou) Co.

T-ALL/LBL is highly aggressive.

Dr.

PA3-17 injection is the first international CAR-T cell injection based on CD7 nano-antibody independently developed by Boshengji (R&D code: PA3-17 injection).

Different from the traditional CD19-CAR-T and BCMA-CAR-T, the development and clinical application of CD7-CAR-T cells are facing huge challenges, including: tumor T cells and normal T cells co-expression of CD7 lead to traditional preparation technology will make CAR-T cells cannot be obtained due to their mutual killing, the residue of tumor T cells in CAR-T cells will cause the product to be unable to release, the temporary decrease of T lymphocytes will increase the risk of infection , and so on

Therefore, many international teams are trying to prepare UCAR-T cells from healthy donors based on the strategy of knocking out CD7 and TCR based on gene editing

Berson Kyrgyzstan since 2012 started to develop CD7 single domain antibodies, has launched a CD7 immune toxins and CD7-CAR-NK's research and development, and finally the successful development of the international's first since the body has a First-in-class potential CD7-CAR -T cells

About Boshengji

It is Boshengji's vision and goal to develop high-quality cellular drugs that cancer patients really need

The company received angel round investment from Suzhou Industrial Park Leading Venture Capital, Suzhou Industrial Park Venture Capital Guidance Fund and other partners in 2012.

At the beginning of this year, Boshengji Pharmaceutical Technology (Suzhou) and Boshengji Anke completed a major internal reorganization, and received a round of investment led by Yuansheng Venture Capital, Puenguoxin Equity Investment and Xiantong Capital

With its first-class cell therapy drug research and development capabilities, fully automated CAR-T cell preparation technology, and advanced lentiviral vector industrial production system, Boshengji has successfully developed a number of cell products and entered the clinical verification phase, covering most of the blood Tumors and some solid tumors

About CD7 target

CD7 is a transmembrane glycoprotein that is expressed on the surface of most T-cell lymphoma and leukemia cells, but is absent on a small part of normal T lymphocytes

As a transmembrane protein, CD7 is rapidly internalized after being combined with antibodies or antibody derivatives, which makes antibodies against CD7 molecules very suitable as a drug delivery tool